Development of an Experimental Model of Cardiac Failure Combined with Type I Diabetes Mellitus

被引：0
|
作者：
S. A. Afanasiev
D. S. Kondratyeva
S. V. Popov
机构：
[1] Siberian Division of the Russian Academy of Medical Sciences,Institute of Cardiology, Tomsk Research Center
来源：
Bulletin of Experimental Biology and Medicine | 2012年 / 153卷
关键词：
heart failure; type 1 diabetes mellitus; streptozotocin; coronary occlusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The doses and mode of streptozotocin injection for modeling heart failure combined with type 1 diabetes mellitus have been determined. Combined disease was induced in animals by injecting the selected streptozotocin dose (60 mg/kg intraperitoneally) at the stage of heart failure formation (2 weeks after coronary occlusion). This protocol of experiment led to development of hyperglycemia, body weight loss, and formation of myocardial cicatrix and hypertrophy corresponding to signs of heart failure paralleled by diabetes mellitus.
引用
收藏
页码：530 / 532
页数：2
相关论文
共 50 条
  • [31] Establishment of a diabetes mellitus type 1 model in the common marmoset
    Yuan, Wenji
    Fukuda, Satsuki
    Inoue, Takashi
    Okochi, Hitoshi
    Sasaki, Erika
    Shimoda, Masayuki
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [32] Heart Failure And Type 2 Diabetes Mellitus: Neurohumoral, Histological And Molecular Interconnections
    Ushakov, A.
    Ivanchenko, V.
    Gagarina, A.
    CURRENT CARDIOLOGY REVIEWS, 2023, 19 (02) : 40 - 55
  • [33] TYPE 2 DIABETES MELLITUS AND HEART FAILURE: INNOVATIVE POSSIBILITIES FOR MANAGEMENT OF PROGNOSIS
    Kobalava, Zh D.
    Yeshniyazov, N. B.
    Medovchshikov, V. V.
    Khasanova, E. R.
    KARDIOLOGIYA, 2019, 59 (04) : 76 - 87
  • [34] Aerobic and strength training in patients with diabetes mellitus type 2 and heart failure
    Niederseer, D.
    Niebauer, J.
    HERZ, 2012, 37 (05) : 499 - 507
  • [35] Safety and Efficacy of Imeglimin for Type 2 Diabetes Mellitus in Patients With Heart Failure
    Nishikawa, Tomoaki
    Higaki, Akinori
    Kurokawa, Keisho
    Yoshimoto, Kohei
    Horie, Rikako
    Nakao, Yasuhisa
    Fujisawa, Tomoki
    Miyazaki, Shigehiro
    Akazawa, Yusuke
    Miyoshi, Toru
    Kawakami, Hiroshi
    Higashi, Haruhiko
    Tamaki, Shunsuke
    Nishimura, Kazuhisa
    Inoue, Katsuji
    Ikeda, Shuntaro
    Yamaguchi, Osamu
    IN VIVO, 2025, 39 (01): : 375 - 380
  • [36] The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
    Anne Pernille Ofstad
    Dan Atar
    Lars Gullestad
    Gisle Langslet
    Odd Erik Johansen
    Heart Failure Reviews, 2018, 23 : 303 - 323
  • [37] Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
    Johansson, Isabelle
    Dahlstrom, Ulf
    Edner, Magnus
    Nasman, Per
    Ryden, Lars
    Norhammar, Anna
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (13) : 1404 - 1416
  • [38] Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
    Patoulias, Dimitrios
    Dimosiari, Athina
    Fragakis, Nikolaos
    FUTURE CARDIOLOGY, 2023, 19 (06) : 301 - 312
  • [39] The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
    Csaba Mátyás
    Balázs Tamás Németh
    Attila Oláh
    László Hidi
    Ede Birtalan
    Dalma Kellermayer
    Mihály Ruppert
    Sevil Korkmaz-Icöz
    Gábor Kökény
    Eszter Mária Horváth
    Gábor Szabó
    Béla Merkely
    Tamás Radovits
    Cardiovascular Diabetology, 14
  • [40] The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
    Matyas, Csaba
    Nemeth, Balaza Tamas
    Olah, Attila
    Hidi, Laszlo
    Birtalan, Ede
    Kellermayar, Dalma
    Ruppert, Mihaly
    Korkmaz-Icoz, Sevil
    Kokeny, Gabor
    Horvath, Eszter Maria
    Szabo, Gabor
    Merkely, Bela
    Radovita, Tamas
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
12345